SNSP-113 / Anagram Therap - LARVOL DELTA

Antibiotics and non-traditional antimicrobial agents for pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials. (PubMed, Expert Opin Investig Drugs) - "Traditional agents in clinical development include β-lactam/β-lactamase inhibitors (funobactam, taniborbactam, QPX2014-xeruborbactam), aminoglycosides (apramycin), polymyxin derivatives (upleganan, MRX-8, and SPR741), fluoroquinolones (MP-376), and lipopolysaccharide transport inhibitors (murepavadin). Non-traditional antibiotics in clinical development include anti-virulence agents (fluorothiazinone), monoclonal antibodies (INFEX-702, TRL-1068, and CMTX-101), bacteriophages (AP-PA02, YPT-01, BX004-A, and WRAIR-PAM-CF1), and miscellaneous agents (AR-501, PLG-0206, SNSP-113, OligoG CF-5/20, and ALX-009). A considerable number of antimicrobial agents, some with novel mechanisms of action, are in clinical phases of development for treating Pseudomonas aeruginosa infections. The urgent need for more therapeutic options necessitates the rapid optimization of progress to introduce new agents into clinical practice."

Journal • Review • Infectious Disease

SNSP113 (PAAG) improves mucociliary transport and lung pathology in the Scnn1b-Tg murine model of CF lung disease. (PubMed, J Cyst Fibros) - "Overall, this study extends the efficacy of SNSP113 as a potential therapeutic to alleviate mucus stasis in muco-obstructive diseases in CF and potentially in related conditions."

Journal • Preclinical • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

COMPARISON STUDY OF UNSUPERVISED REMOTE AND SUPERVISED CLINIC SPIROMETRY MEASUREMENTS IN A CLINICAL TRIAL SETTING (CHEST 2023) - "Here we analyzed the data from a phase 2a clinical trial for a novel inhaled polycationic glycopolymer (SNSP113, Synspire Pharmaceuticals) utilizing both clinic and remote spirometry (NuvoAir Air Next device) We utilized the data from this phase 2a study which had the goal of determining safety and performance of long-term (28-days) administration in a cystic fibrosis population... This analysis shows bioequivalence using the FDA standard for spirometry assessed in the supervised setting in the clinic and in the unsupervised setting using NuvoAir Air Next remotely, also, our results provide quantification of accuracy of remote spirometry for clinical use. CLINICAL IMPLICATIONS: The desire to reduce the number of in person clinic visits for patient management and clinical trial outcome assessment has led to the consideration of utilizing app-based systems such as NuvoAir. The demonstration that the data from such systems used by the patients remotely give bioequivalent..."

Clinical • Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Synspira Therapeutics Announces Expanded Agreement with Cystic Fibrosis Foundation to Advance Promising Treatments for Cystic Fibrosis (PRNewswire) - "Synspira Therapeutics...announced today that the Cystic Fibrosis Foundation has made equity and structured investments in the company of up to $14 million in additional funding. The new funding brings the Foundation's total commitment to $22.55 million. 'This investment and development collaboration will enable Synspira to complete preclinical and initial clinical development for SNSP003 while also advancing SNSP113 through late stage clinical studies,'...the company's novel polycationic glycopolymer SNSP113, currently in Phase 2 clinical studies, for the treatment of pulmonary infections and complications. In addition, the funding will accelerate SNSP003..."

Financing • Cystic Fibrosis • Infectious Disease

[VIRTUAL] EFFECTS OF SNSP113 (PAAG) ON MUCUS OBSTRUCTION IN THE -ENAC MURINE MODEL OF CF LUNG DISEASE (NACFC 2020) - "SNSP113 improves mucus obstruction in -ENaC mice caused by airway dehydration in vivo after a 28-day treatment. Further development of SNSP113 could lead to a novel approach to treat mucus stasis in CF."

Preclinical • Immunology • Inflammation • Respiratory Diseases • PTPRC

[VIRTUAL] SNSP113 ERADICATES MRSA, POTENTIATES EFFECT OF ANTIBIOTICS, AND TREATS RECALCITRANT BACTERIA (NACFC 2020) - "MRSA is most commonly treated with last-line antibiotics vancomycin and linezolid. SNSP113, a polycationic glycopolymer, eradicates MRSA clinical isolates in vitro including disrupting recalcitrant biofilms and persister-like cells. Further, SNSP113 synergizes with antibiotics and also reduces the concentration of methicillin needed to kill MRSA. SNSP113 may also reduce inflammation and cellularity in the lungs."

Cystic Fibrosis • Fibrosis • Genetic Disorders • Immunology • Inflammation • Respiratory Diseases

A study of safety, tolerability and effect of SNSP113 in Cystic Fibrosis Az SNSP113 biztonságosságára, tolerálhatóságára és hatásosságára irányuló vizsgálat cisztás fibrózisban (clinicaltrialsregister.eu) - P2; N=56; Ongoing; Sponsor: Synspira Therapeutics, Inc.

Clinical • New P2 trial